PureIMS has appointed Frank Lambert as Executive Director Commercialization. Lambert, who was most recently Executive Director of Business Development for Early Development Services at ICON, will lead commercialization efforts for the company’s Cyclops pre-filled disposable dry powder inhaler.
PureIMS has Cyclops DPI formulations of levodopa, epinephrine, and colistin in its own pipeline and is already partnered on several other development projects. In July 2021, the company announced that it had partnered with Sever Pharma Solutions and Radboudumc on development of inhaled tigecycline for the treatment of multi-drug resistant Mycobacterium abscessus lung infections.
PureIMS CEO Jaap Wieling said, “I am very pleased to welcome Frank to our team to capitalize on the opportunities we see for Cyclops for a broad range of compounds and indications. Having worked in early-stage clinical pharmacology for so long Frank will bridge Cyclops to developers of new delivery products with marketed compounds as well as NCE’s and NBE’s.”
Read the PureIMS press release.
